By Adria Calatayud
Sanofi said its Tzield drug met the primary goal of a phase 3 clinical trial, showing potential to slow the progression of a type of diabetes in newly diagnosed children and adolescents.
The French pharmaceutical giant said Tzield demonstrated in the trial superior beta-cell preservation compared with placebo, and that this indicates its potential to slow the progression of Stage 3 type 1 diabetes in this population.
The trial studied the efficacy and safety of the drug in children and adolescents aged 8-17 years, the company said.
Results for the study’s key secondary goals, which included a numerically lower mean insulin dose, weren’t considered statistically significant, Sanofi said.
Sanofi added Tzield to its portfolio through the acquisition of Provention Bio, which was completed in April.
Write to Adria Calatayud at adria.calatayud@dowjones.com
Read the full article here